TriangleNCT03433001 · OUTCOME
Patient-Reported Outcome Health-Related Quality of Life (HRQoL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global Health Status Score
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Score on a Scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and End of Treatment (Up to 37 cycles, each cycle was of 28 days)
What was measured
EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores of Global Health Status in EORTC QLQ-C30 were linearly transformed to a total score between 0-100 and reported, with a high score indicating better QOL.
Analysis population: Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.
Groups in this outcome
Ixazomib + Lenalidomide + Dexamethasone
Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
| Group | Source count |
|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 279 |
Reported measurements
Baseline
| Group | Source count |
|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 279 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 59.95 | 22.472 | Not reported | Not reported | Not reported |
End of Treatment
| Group | Source count |
|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 2 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 75.00 | 11.785 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 22.472
- value
- 59.95
- denoms
- counts
- group Id
- OG000
- value
- 279
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 11.785
- value
- 75.00
- denoms
- counts
- group Id
- OG000
- value
- 2
- units
- Participants
- title
- End of Treatment
- denoms
- counts
- group Id
- OG000
- value
- 279
- units
- Participants
- description
- EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=Very poor \[worst\] to 7= Excellent \[best\]). Raw scores of Global Health Status in EORTC QLQ-C30 were linearly transformed to a total score between 0-100 and reported, with a high score indicating better QOL.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
- id
- OG000
- title
- Ixazomib + Lenalidomide + Dexamethasone
- param Type
- MEAN
- population Description
- Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.
- reporting Status
- POSTED
- time Frame
- Baseline and End of Treatment (Up to 37 cycles, each cycle was of 28 days)
- title
- Patient-Reported Outcome Health-Related Quality of Life (HRQoL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Global Health Status Score
- type
- SECONDARY
- unit Of Measure
- Score on a Scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice